Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 25, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs. On September 22, 2006, this re-valuation resulted in an increase in the notional allocation of Ordinary Share ADRs at a price of $53.99 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- Transaction Date: September 22, 2006.
- Transaction Price: $53.99 per share for GSK Ordinary Share ADRs.
- Involved Parties: Dr. M. Slaoui (9 shares) and Dr. R. Greig (4 shares).
- Context: The transaction was an automatic increase in notional allocation due to a plan re-valuation, not a direct market purchase.